PI4K2B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL580610	0.58	10/20
SCHEMBL8273	0.54	10/20
SCHEMBL9120	0.54	10/20
SCHEMBL258584	0.54	10/20
SCHEMBL106573	0.59	9/20
SCHEMBL42335	0.57	8/20
SCHEMBL42314	0.56	8/20
SCHEMBL8566	0.53	8/20
SCHEMBL24640	0.50	8/20
SCHEMBL385843	0.50	7/20
SCHEMBL134910	0.54	6/20
SCHEMBL397509	0.50	6/20
SCHEMBL48258	0.41	6/20
SCHEMBL179434	1.00	5/20
SCHEMBL179409	0.71	5/20
SCHEMBL179437	0.71	5/20
SCHEMBL179458	0.71	5/20
SCHEMBL179551	0.54	5/20
SCHEMBL397656	0.45	5/20
SCHEMBL8565	0.37	5/20

Clinical trials — most relevant to PI4K2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial	PHASE2/PHASE3	UNKNOWN
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia	PHASE2	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Study of Proteus Syndrome and Related Congenital Disorders	nan	RECRUITING
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PI4K2B binder may also engage these)

Protein	Name	Similarity
Q6DCQ8	—	1.000	Q6DCQ8 →
Q8CBQ5	—	1.000	Q8CBQ5 →
Q5ZIK0	—	1.000	Q5ZIK0 →
Q5XIL2	—	1.000	Q5XIL2 →
Q49GP5	—	1.000	Q49GP5 →
Q28G26	—	1.000	Q28G26 →
Q99M64	—	0.999	Q99M64 →
PI4K2A	Phosphatidylinositol 4-kinase type 2-alpha	0.999	landscape →
Q505I0	—	0.998	Q505I0 →
Q2TBE6	—	0.997	Q2TBE6 →
Q6PE18	—	0.995	Q6PE18 →
Q08B31	—	0.994	Q08B31 →
F4K493	—	0.990	F4K493 →
Q9VLA1	—	0.989	Q9VLA1 →
A4VCL2	—	0.989	A4VCL2 →
Q9S7D1	—	0.989	Q9S7D1 →
Q95JR3	—	0.988	Q95JR3 →
O22199	—	0.988	O22199 →
Q09298	—	0.988	Q09298 →
Q8BMD7	—	0.987	Q8BMD7 →
Q8GZ81	—	0.987	Q8GZ81 →
Q7XZU3	—	0.987	Q7XZU3 →
D3YWQ0	—	0.987	D3YWQ0 →
Q6DW74	—	0.987	Q6DW74 →
O23273	—	0.987	O23273 →
P93002	—	0.987	P93002 →
Q9R1W3	—	0.987	Q9R1W3 →
Q9S7P5	—	0.987	Q9S7P5 →
Q5ICL9	—	0.987	Q5ICL9 →
Q9XTW2	—	0.987	Q9XTW2 →